Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil ON long-term open-label extension of spesolimab in generalized pustular psoriasis
CTR20200484Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Started Sep 2020; status: active.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20200484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200484.